Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PAT-1251 Safety and PK Study in Healthy Adults
NCT02852551Phase 1Completed
- Sponsor
- PharmAkea Therapeutics
- Start
- Jul 2016
- Primary completion
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of lenumlostat in idiopathic pulmonary fibrosis (IPF), myelofibrosis (MF) and Liver Fibrosis (LF) (4 arms), sponsored by PharmAkea Therapeutics. Primary endpoint: Incidence of Treatment-Emergent Adverse Events. Started Jul 2016; status: completed.
02
Drugs
lenumlostat
03
Conditions
idiopathic pulmonary fibrosis (IPF)myelofibrosis (MF)Liver Fibrosis (LF)
Beyond the preview
Go deeper on NCT02852551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02852551.